AstraZeneca
2025.08.04
15:16
AstraZeneca's shares fell 0.6% in European trading.
2025.08.01
15:11
AstraZeneca's European shares fell 3%.
2025.07.29
22:17
AstraZeneca's chief financial officer: U.S. tariffs will not have a significant impact on the company; if there is any impact, it will be "very short-lived."
19:38
AstraZeneca CEO: Trump administration is considering its proposal to lower drug prices.
19:26
AstraZeneca CEO: US production will be fully localized within a few months.
19:23
AstraZeneca CEO: The company is almost self-sufficient in the United States.
19:22
AstraZeneca CEO: The US government has not promised the company can avoid tariffs.
19:21
AstraZeneca CEO: Europe is falling behind the United States and China.
19:20
AstraZeneca CEO: There is almost no innovation emerging in Europe.
19:18
AstraZeneca CEO: Meets with officials to discuss US drug production.
18:27
AstraZeneca's revenue in China reached US$3.515 billion in the first half of the year and will expand its presence in China
On July 29, AstraZeneca announced its results for the first half of 2025, achieving total revenue of $28.045 billion, an 11% year-on-year increase, including product revenue of $27.963 billion, an 11% year-on-year increase. By region, in the first half of the year, AstraZeneca's US market revenue reached $11.97 billion, a year-on-year increase of 12%, and its emerging market revenue reached $7.697 billion, a year-on-year increase of 12%. Revenue in China reached $3.515 billion, a year-on-year increase of 5%, accounting for over 12% of global revenue. "We are optimistic about China's innovation potential and will continue to expand our research and development presence in China," AstraZeneca disclosed. In March, the company announced a $2.5 billion investment plan in China, which included the establishment of its sixth global strategic research and development center in Beijing. Currently, two of AstraZeneca's six global strategic research and development centers are located in China.
2025.07.22
23:44
U.S. President Donald Trump praised AstraZeneca's (AZN.O) investments in the United States.
06:05
AstraZeneca (AZN.O): Plans to invest $50 billion in drug manufacturing and research and development in the United States.
2025.07.16
15:10
AstraZeneca shares fell 1% after Anselamimab failed to hit its main goal in a late-stage clinical trial.
2025.07.15
19:21
AstraZeneca's new hypertension drug succeeds in Phase III
Today, the reporter learned from AstraZeneca that its research drug Baxdrostat achieved the primary and all secondary endpoints in the BaxHTN Phase III clinical trial for patients with uncontrolled or refractory hypertension. According to the positive results of the BaxHTN Phase III trial, compared with placebo, both doses of Baxdrostat (2 mg and 1 mg) showed statistically significant and clinically significant reductions in patients' sitting systolic blood pressure (SBP) at 12 weeks of treatment, and the trial also successfully achieved all secondary endpoints.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Novo Nordisk (NVO.N): The downward revision of its fiscal year sales forecast is related to declining sales of its weight loss drug Wegovy in the United States.

2025-07-29

Toyota Motor Corp. is expected to decide as early as Wednesday evening whether to resume operations at its Japanese factories.

2025-07-30

CATL's losses widened in the afternoon, with A shares falling more than 4% to below 280 yuan and H shares falling more than 7%.

2025-07-30

BYD: Sales of new energy vehicles in July were 344,296 units. The cumulative sales of new energy vehicles from January to July were 2,490,250 units, a year-on-year increase of 27.35%.

2025-08-01

Amazon (AMZN.O) shares plummeted 7.1 percent, wiping out $178 billion in market value.

2025-08-01

ASIA TECH WIRE

Grasp technology trends

Download